Volume 2, Issue 3, October 2023

					View Volume 2, Issue 3, October 2023
  • Bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for indolent lymphoma
  • The role of FDG-PET scanning and PET-adapted therapy in the primary treatment of Hodgkin lymphoma: A primer for clinicians
  • Monoclonal gammopathy of clinical and undetermined significance
  • Frontline treatment of aggressive B-cell lymphoma
  • Chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma: The evolving Canadian landscape
Published: 2023-11-07